Jeffery Bowers, MD
Family Medicine · Bangor, MENPI 1013958552
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Novo Nordisk at 25.6% of the total. Reporting peaked in 2019 at $565 and has fallen 51.1% since, to $276 in 2025. Among family medicine clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 82 payments — averaging $12.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$264
- GSK$124
- Lilly USA, LLC$104
- Pfizer$88
- Amarin Pharma, Inc.$68
- AstraZeneca$64
- plus $316 from 14 others
What the payments were for
- Food & beverage$1,028100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $264 |
| GSK | 13 | $124 |
| Lilly USA, LLC | 7 | $104 |
| Pfizer | 6 | $88 |
| Amarin Pharma, Inc. | 3 | $68 |
| AstraZeneca | 5 | $64 |
| Boehringer Ingelheim | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $48 |
| Astellas Pharma US Inc | 3 | $39 |
| Merck | 2 | $23 |
| Exact Sciences | 1 | $18 |
| AbbVie | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Valeritas, Inc. | 1 | $15 |
| Medtronic | 1 | $14 |
| Amgen | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$1,028 in reported general payments places this provider in the 90th percentile of 466 family medicine providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 106 | $106,869 |
| JardianceEmpagliflozin | 68 | $87,001 |
| TrulicityDulaglutide | 49 | $55,571 |
| OzempicSemaglutide | 45 | $42,412 |
| XareltoRivaroxaban | 25 | $36,576 |
| JanuviaSitagliptin Phosphate | 29 | $35,184 |
| FarxigaDapagliflozin Propanediol | 18 | $27,919 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $23,104 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $22,004 |
| MounjaroTirzepatide | 23 | $20,536 |
| EntrestoSacubitril/Valsartan | 14 | $17,516 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $17,000 |
| MyrbetriqMirabegron | 12 | $14,274 |
| TradjentaLinagliptin | 17 | $13,859 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $6,611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $88 | $106,869106 claims |
| Boehringer IngelheimJardiance, Tradjenta | $59 | $100,86085 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $104 | $76,10872 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $124 | $62,10792 claims |
| Novo NordiskOzempic, Novolog | $264 | $46,60957 claims |
| Johnson & JohnsonXarelto | $13 | $36,57625 claims |
| MerckJanuvia | $23 | $35,18429 claims |
| AstraZenecaFarxiga, Nexium | $64 | $33,51531 claims |
| Astellas Pharma US IncMyrbetriq | $39 | $14,27412 claims |
| AbbVieSynthroid | $17 | $2,22321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 466 family medicine providers in Maine.
Other family medicine in Bangor
- Jessica Bloom FosterBangor$14K
- Alexandra CraigBangor$1K
- Bryan LundquistBangor$895
- Kristy Murray-PulsiferSouth Portland$55K
- Albert HartmanLewiston$33K
- Brian KnightonFreeport$29K
- Edward YoonPortland$27K
- Jennifer FreeseVeazie$19K
- Kohar der SimonianFalmouth$18K
- Cecily CannonKennebunk$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.